ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates
MHRA Drug Safety Updates

 

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

 TitleCreatedDownload
application/pdfMHRA Drug Safety Update November 2022 PDF.pdf (289KB)30/11/2022Download
 Dupilumab (Dupixentâ–¼): risk of ocular adverse reactions and need for prompt management. Consultation with healthcare professionals: please complete our consultation to help influence how we... 
application/pdfMHRA Drug Safety Update October-2022-DSU-PDF.pdf (243KB)25/11/2022Download
 This month, we ask healthcare professionals to support our annual #MedSafetyWeek social media campaign, which will take place 7 to 13 November 2022. This year's focus is the importance of reporting... 
application/pdfMHRA Drug Safety Update September-2022-DSU-PDF.pdf (286KB)27/09/2022Download
  
application/pdfMHRA Drug Safety Update August-2022-DSU-PDF.pdf (258KB)24/08/2022Download
 Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists. COVID-19 vaccines and medicines: updates for August... 
application/pdfMHRA Drug Safety Update July-2022-DSU-PDF.pdf (282KB)21/07/2022Download
  
application/pdfMHRA Drug Safety Update June-2022-DSU-PDF.pdf (255KB)21/07/2022Download
  
application/pdfMHRA Drug Safety Update May-2022-DSU-PDF.pdf (207KB)21/07/2022Download
  
application/pdfMHRA Drug Safety Update April 2022.pdf (262KB)25/04/2022Download
  
application/pdfMHRA Drug Safety Update March-2022-DSU-PDF.pdf (420KB)15/03/2022Download
 Cladribine (Mavenclad): new advice to minimise risk of serious liver injury, Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision, Metformin in... 
application/pdfDrug Safety Update February -2022-_PDF.pdf (363KB)15/02/2022Download
  
application/pdfDrug Safety Update January -2022-_PDF.pdf (247KB)19/01/2022Download
  
application/pdfDrug Safety Update December 2020-DSU-PDF-1712.pdf (263KB)10/12/2021Download
 Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. Venetoclax (Venclyxtoâ–¼): updated recommendations on tumour lysis syndrome (TLS).... 
Page: [1] [2] [3] [4] [5] [6] [7] [8]
[ Next » ]